Compare Eli Lilly And Co (LLY) vs Southwest Airlines Co (LUV) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Southwest Airlines (LUV) trades at $48.28, up 0.42% today, with a neutral technical signal and mixed earnings history. Recent Q1 2026 EPS missed expectations, but Q4 2025 and Q3 2025 beat. Financials show modest revenue growth to $28.06B in 2025, but net income margin is thin at 2.83%. Analyst consensus is mixed with 42% buy, 47% hold, and 11% sell ratings, and a $52.47 price target implies potential upside. Key news highlights Q2 2026 earnings due July 23, 2026, amid fuel cost volatility and travel demand resilience.

LUV presents a cautious opportunity with upside to the consensus target, supported by operational improvements and sector tailwinds, but risks from fuel price swings, execution challenges, and thin margins warrant careful monitoring. The stock's valuation at a P/E of 32.05 appears elevated relative to earnings growth, requiring strong future performance to justify current levels.